natgillin/translations-raw huggingface dataset:
or in any case a pharmaceutically acceptable salt thereof. A pharmaceutical composition, comprising the compound according to one of the claims 1 to 11 and a pharmaceutical acceptable carrier or excipient. 
Farmaceutski sastav, naznačen time, da sadrži spoj prema bilo kojem zahtjevu 1 do 7, ili njegovu farmaceutski prihvatljivu sol i njegov farmaceutski prihvatljiv nosač ili ekscipijent.
The method according to any one of claims 13 or 14, characterized in that the particle sizes within a fraction are in a range of from 10 - 30 mm, preferably in a range of from 30 - 70 mm, more preferably in a range of from 60-120 mm. 
Postupak prema bilo kojem od zahtjeva 13 ili 14, naznačen time da su veličine čestica unutar frakcije u rasponu od 10 - 30 mm, poželjno u rasponu od 30 - 70 mm, još poželjnije u rasponu od 60-120 mm.
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically active amount of the compound as claimed in any of claims 1 to 5. 
Farmaceutski sastav, naznačen time, da sadrži farmaceutski prihvatljiv nosač i terapeutski učinkovitu količinu spoja prema bilo kojem od zahtjeva od 1 do 5.
The compound as claimed in any of claims 1 to 5 for use in the treatment of substance abuse disorders and impulse control disorders. 
Spoj prema bilo kojem od zahtjeva 1 do 5, naznačen time, da se koristi kod liječenja poremećaja zloupotrebe tvari i poremećaja kontroliranja nagona.
The plant of claim 9, wherein the first and the second welding devices (5, 6) are arranged for welding at least partially-overlapping portions of the edge of the beaker-shaped filter (105). 
Postrojenje prema zahtjevu 9, naznačeno time, da su prva i druga zavarivačka stanica (5, 6) raspoređene za zavarivanje barem djelomično preklapajućih komada brida filtera u obliku čašice (105).
or a tautomer, stereoisomer, polymorph, or ester thereof or a pharmaceutically acceptable salt of the compound, tautomer, stereoisomer, polymorph, or ester. 
ili njegov tautomer, stereoizomer, polimorf ili ester, ili farmaceutski prihvatljiva sol spoja, tautomera, stereoizomera, polimorfa ili estera.
The compound, tautomer, pharmaceutically acceptable salt, or the pharmaceutically acceptable salt of the tautomer thereof of Claim 28 in which the at least one additional agent for the treatment of cancer is selected from irinotecan, topotecan, gemcitabine, 5-fluorouracil, leucovorin carboplatin, cisplatin, taxanes, tezacitabine, cyclophosphamide, vinca alkaloids, imatinib, anthracyclines, rituximab, and trastuzumab. 
Spoj, tautomer, farmaceutski prihvatljiva sol, ili farmaceutski prihvatljiva sol njegovog tautomera prema zahtjevu 28, naznačen(a) time, da je najmanje jedan dodatni agens za liječenje raka odabran od sljedećih: irinotekan, topotekan, gemcitabin, 5-fluorouracil, leukovorin karboplatin, cisplatin, taksani, tezacitabin, ciklofosfamid, vinca alkaloidi, imatinib, antraciklini, rituksimab i trastuzumab.
A compound, tautomer, pharmaceutically acceptable salt, or a pharmaceutically acceptable salt of the tautomer thereof of Claim 1 or 24, for use in a method of inhibiting at least one serine/threonine kinase in the MAPK signaling pathway in a subject, or treating a biological condition mediated by a serine/threonine kinase in the MAPK signaling pathway in a subject, comprising: administering to the subject a composition comprising the compound, tautomer, pharmaceutically acceptable salt, or the pharmaceutically acceptable salt of the tautomer thereof. 
Spoj, tautomer, farmaceutski prihvatljiva sol, ili farmaceutski prihvatljiva sol njegovog tautomera prema zahtjevu 1 ili 24, naznačen(a) time, da se koristi u postupku inhibiranja najmanje jedne serin/treonin kinaze u MAPK signalnim putovima kod subjekta, ili liječenja biološkog stanja posredovanog serin/treonin kinazom u MAPK signalnim putovima kod subjekta, a postupak obuhvaća davanje subjektu sastav koji sadrži spoj, tautomer, farmaceutski prihvatljivu sol, ili farmaceutski prihvatljivu sol njegovog tautomera.
The compound, tautomer, pharmaceutically acceptable salt, or the pharmaceutically acceptable salt of the tautomer thereof of Claim 33, wherein the biological condition is selected from the group consisting of melanoma, papillary thyroid cancer, ovarian cancer, colon cancer, pancreatic cancer, lung cancer, and leukemia. 
Spoj, tautomer, farmaceutski prihvatljiva sol, ili farmaceutski prihvatljiva sol njegovog tautomera prema zahtjevu 33, naznačen(a) time, da je biološko stanje odabrano iz skupine koju čine melanom, papilarni rak štitnjače, rak jajnika, rak debelog crijeva, rak gušterače, rak pluća i leukemija.
The compound, tautomer, pharmaceutically acceptable salt, or the pharmaceutically acceptable salt of the tautomer thereof of Claim 38, wherein the biological condition is selected from the group consisting of mast cell leukemia, erythroleukemia, germ cell tumors, small-cell lung carcinoma, gastrointestinal stromal tumors, acute myelogenous leukemia, neuroblastoma, melanoma, multiple myeloma, ovarian carcinoma, and breast carcinoma. 
Spoj, tautomer, farmaceutski prihvatljiva sol, ili farmaceutski prihvatljiva sol njegovog tautomera prema zahtjevu 38, naznačen(a) time, da je biološko stanje odabrano iz skupine koju čine leukemija mastocita, eritroleukemija, tumori zametnih stanica, karcinom malih plućnih stanica, gastrointestinalni stromalni tumori, akutna mijeloična leukemija, neuroblastom, melanom, multipli mijelom, karcinom jajnika i karcinom dojke.
Compounds of formula (I): wherein: 
Spojevi formule (I):
represents an optional single bond; 
[image] predstavlja izbornu jednostruku vezu;
Compounds according to claim 1 or 2 of formula (II): 
Spojevi u skladu s patentnim zahtjevom 1 ili 2, naznačeni time što su spojevi formule (II):
Compounds according to claims 1 to 3 wherein W and W ' are the same or different and are OH, OMe, OEt, NHCONH2, SMe. 
Spojevi u skladu s patentnim zahtjevima 1 do 3, naznačeni time što W i W' su isti ili različiti i jesu OH, OMe, OEt, NHCONH2, SMe.
Compounds according to claim 1 or 2 of formula: or 
Spojevi u skladu s patentnim zahtjevom 1 ili 2, naznačeni time što su spojevi formule:
or their pharmaceutically acceptable salts, hydrates, or hydrated salts, or the polymorphic crystalline structures of these compounds or their optical isomers, racemates, diastereomers or enantiomers, said compound being covalently bonded to a cell binding agent through said linker. 
ili njihove farmaceutski prihvatljive soli, hidrati ili hidratirane soli, ili polimorfne kristalne strukture tih spojeva ili njihovi optički izomeri, racemati, dijastereomeri ili enantiomeri, gdje je navedeni spoj kovalentno vezan na sredstvo za vezanje na stanicu preko navedene spojnice.
A conjugate according to claim 12 or 13 wherein said cell binding agent is chosen from antibodies, fragment of an antibody that contains at least one binding site, lymphokines, hormones, growth factors, nutrient-transport molecules. 
Konjugat u skladu s patentnim zahtjevom 12 ili 13, naznačen time što navedeno sredstvo za vezanje na stanicu se bira između protutijela, fragmenta protutijela koji sadrži najmanje jedno mjesto vezanja, limfokina, hormona, čimbenika rasta, molekula za transport nutricijenata.
Process to prepare a conjugate wherein a free or protected-thiol containing cell-binding agent is reacted with a disulfide- or thiol-containing compound of any one of claims 1 to 11, the cell-binding agent being a peptide or an antibody modified by a cross-linking reagent. 
Postupak dobivanja konjugata, naznačen time što slobodno ili zaštićeno sredstvo za vezanje na stanicu koje sadrži tiol reagira sa spojem koji sadrži disulfid ili tiol, u skladu s bilo kojim od patentnih zahtjeva 1 do 11, gdje je sredstvo za vezanje na stanicu peptid ili protutijelo modificirano umrežujućim reagensom.
Process according to claims 17 to 22 wherein the conjugate is purified: 
Postupak u skladu s patentnim zahtjevima 17 do 22, naznačen time što konjugat se pročišćuje:
The compound according to claims 1-16 wherein R3 is 1,4 diazacycloheptan-1-yl, optionally substituted with (1-4C)alkylcarbonyl or (3-6C)cycloalkylcarbonyl. 
Spoj prema patentnim zahtjevima 1-16, naznačen time što, R3 je 1,4 diazacikloheptan-1-il, izborno supstituiran sa (1-)alkilkarbonil ili (3-)cikloalkilkarbonil.
4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one as crystalline Form A, the compound having the following characteristic peaks in a powder XRD: 
Spoj, naznačen time, da je to 4-[3-(4-ciklopropankarbonil-piperazin-1-karbonil)-4-fluoro-benzil]-2H-ftalazin-1-on kao kristalni oblik A, koji ima sljedeće karakteristične vršne točke u prahu XRD: [image]
5 29.2 The compound of claim 1 having the following characteristic peaks in a powder XRD: 
Spoj prema zahtjevu 1, naznačen time, da ima sljedeće karakteristične vršne točke u prahu XRD:
10 26.1 The compound of either claim 1 or claim 2, which begins melting at 210.1°C ±1°C when heated from 25°C to 325°C at 10°C per minute in DSC. 
Spoj prema zahtjevu 1 ili zahtjevu 2, naznačen time, da se počinje taliti na 210,1°C ± 1°C kada se zagrijava od 25°C do 325°C po 10°C u minuti u DSC.
if the original solvent is not ethanol, treating the crystalline compound A with ethanol; 
ako izvorno otapalo nije etanol, tretiranje kristalnog spoja A etanolom;
treating the crystalline compound A with water to remove trapped ethanol; 
tretiranje kristalnog spoja A vodom da se odstrani zaostali etanol;
drying the resulting product. 
sušenje rezultirajućeg proizvoda.
if the original solvent used in the synthesis of compound A in the crystalline form is not a mixture of water and a C1-2 alcohol, heating the compound with a mixture of water and a C1-2 alcohol; 
ako izvorno otapalo korišteno u sintezi spoja A u kristalnom obliku nije mješavina vode i C1-2 alkohola, zagrijavanje spoja mješavinom vode i C1-2 alkohola;
distilling the mixture at ambient pressure; and 
destilacija mješavine uz tlak okoline; i
suspending compound A in a mixture of water and a C1-2 alcohol as the solvent; 
suspendiranje spoja A u mješavini vode i C1-2 alkohola kao otapala;
cooling the solution and seeding with compound A as Form A; 
hlađenje otopine i zasijavanje spojem A koji je u obliku A;
A pharmaceutical composition comprising a compound according to any one of claims 1 to 3 and a pharmaceutically acceptable carrier or diluent. 
Farmaceutski sastav, naznačen time, da sadrži spoj prema bilo kojem od zahtjeva 1 do 3 i farmaceutski prihvatljiv nosač ili razrjeđivač.
The use of a compound according to any one of claims 1 to 3 in the preparation of a medicament for use as an adjunct in cancer therapy or for potentiating tumour cells for treatment with ionizing radiation or chemotherapeutic agents. 
Uporaba spoja prema bilo kojem od zahtjeva 1 do 3, naznačena time, da je za pripravljanje lijeka koji se koristi kao dopuna u liječenju raka ili za potencijaciju tumorskih stanica za liječenje s ionizacijskom radijacijom ili sa kemoterapeutskim sredstvima.
a first heating input (72a) capable of delivering warmed gas into a first zone of the chamber; 
prvi ulaz za grijanje (72a) koji može dovoditi zagrijani plin u prvu zonu komore;
a second heating input (72b) capable of delivering warmed gas into a second zone of the chamber; 
drugi ulaz za grijanje (72b) koji može dovoditi zagrijani plin u drugu zonu komore;
a first cooling input (92a) capable of delivering cooled gas into one zone of the chamber; 
prvi ulaz za hlađenje (92a) koji može dovoditi ohlađeni plin u jednu zonu komore;
The soak furnace as set forth in claim 1 wherein the first set of baffles (48) provides different temperatures in the zones by adjusting between the open position and the closed position. 
Potopna peć kako je navedeno u zahtjevu 1 naznačena time da prvi niz pregrada (54) pomoću podešavanja između otvorenog položaja i zatvorenog položaja, pruža različite temperature u zonama.
The soak furnace as set forth in claim 7 wherein the warmed gas is supplied to the fan by a direct fire strip annealing furnace. 
Potopna peć kako je navedeno u zahtjevu 7 naznačena time da se zagrijani plin dobavlja prema ventilatoru izravno od peći za žarenje trake.
The soak furnace as set forth in claim 12 wherein each of the four heating inputs defines a zone in the chamber with the first zone is located near the first opening and the fourth zone is located near the second opening and the first set of baffles is located in the third zone. 
Potopna peć kako je navedeno u zahtjevu 12 naznačena time da svaki od četiri ulaza za grijanje određuje zonu u komori, te je prva zona smještena u blizini prvog otvora, a četvrta zona je smještena u blizini drugog otvora, dok je prvi niz pregrada smješten u trećoj zoni.
The soak furnace as set forth in claim 16 wherein the cooling apparatus includes a fan, an input capable of allowing cool gas into the chamber, a valve capable of regulating the flow of cool air into the chamber, and a conduit connecting the fan to the input, the valve being connected to the conduit. 
Potopna peć kako je navedeno u zahtjevu 16 naznačena time da naprava za hlađenje uključuje ventilator, ulaz kroz koji može hladni plin ulaziti u komoru, ventil koji može regulirati protok hladnog zraka u komoru, te kanal koji povezuje ventilator sa ulazom, a ventil je spojen sa kanalom.
A soak furnace (22) for use in the heat treatment of a zinc coated metal strip to complete galvannealing of the metal strip or for use in after pot cooling in galvanizing a metal strip including: 
Potopna peć (22) za uporabu kod toplinske obrade cinkom prevučene metalne trake radi završetka postupka galvano žarenja metalne trake ili za uporabu kod naknadnog hlađenja u posudi kod galvanizacije metalne trake naznačena time da sadrži:
a chamber (43) defined by four walls (42), a first opening (44) and a second opening (46); 
komoru (43) omeđenu sa četiri stjenke (42), prvi otvor (44) i drugi otvor (46);
at least one cooling apparatus including a fan, a conduit including a first input allowing cooling air pumped by the fan to enter the chamber and a first valve capable of controlling the amount of cool air being directed into the chamber by the fan; 
najmanje jednu napravu za hlađenje koja uključuje ventilator, kanal uključujući prvi ulaz koji omogućuje ulazak hladnog zraka koji se dobavlja pomoću ventilatora u komoru i prvi ventil koji može kontrolirati količinu hladnog zraka koji se usmjerava u komoru pomoću ventilatora;
a first pair of baffles (54) located in the third zone; and a second pair of baffles (52) located in the fourth zone, the fourth zone being located near the second opening at the top of the soak; 
prvi par pregrada (54) smješten u trećoj zoni; te drugi par pregrada (52) smješten u četvrtoj zoni, te je četvrta zona smještena u blizini drugog otvora na gornjoj strani od zagrijavanja;
wherein the first pair of baffles (54) and the second pair of baffles (52) provide different temperatures in the zones by adjusting between a closed position or partially closed position and an open position defining different temperature regions in the chamber. 
pri čemu prvi par pregrada (54) i drugi par pregrada (52) pružaju različite temperature u zonama pomoću podešavanja između zatvorenog položaja ili djelomično zatvorenog položaja i otvorenog položaja koji definiraju temperaturna područja u komori.
The soak furnace as set forth in claim 21 wherein the fan is connected to provide heated air from the exhaust gas of a direct fire strip annealing furnace. 
Potopna peć kako je navedeno u zahtjevu 21 naznačena time da je ventilator povezan da dobavlja zagrijani zrak od ispušnih plinova izravno od peći za žarenje trake.
The soak furnace as set forth in claim 21 wherein the conduit of the cooling apparatus further includes a second input allowing cooling air pumped by the fan to enter the chamber and a second valve capable of controlling the amount of cool air pumped into the interior by the fan through the second input. 
Potopna peć kako je navedeno u zahtjevu 21 naznačena time cjevovod uređaja za hlađenje nadalje uključuju drugi ulaz, koji omogućava zraku za hlađenje, što ga usmjerava ventilator, ulaz u komoru i drugi ventil, koji može kontrolirati količinu hladnog zraka, koji u unutrašnjost, kroz drugi ulaz dobavlja ventilator.
The soak furnace as set forth in claim 24 wherein the first input is connected to at least one of the zones and the second input is connected to a second of the zones. 
Potopna peć kako je navedeno u zahtjevu 24 naznačena time da je prvi ulaz spojen sa najmanje jednom zonom i drugi ulaz je spojen sa drugom zonom.
The soak furnace as set forth in claim 26 wherein the first input of the second cooling apparatus is in a different zone than the first input of the first cooling apparatus. 
Potopna peć kako je navedeno u zahtjevu 26 naznačena time da prvi ulaz druge naprave za hlađenje je u različitoj zoni nego prvi ulaz prve naprave za hlađenje.
The soak furnace as set forth in claim 21 further including a first set of doors configured to selectively restrict the flow of air through the first opening and a second set of doors configured to selectively restrict the flow of air through the second opening. 
Potopna peć kako je navedeno u zahtjevu 21 naznačena time da nadalje uključuje prvi niz vrata podešenih da selektivno ograničavaju protok zraka kroz prvi otvor i drugi niz vrata podešenih da selektivno ograničavaju protok zraka kroz drugi otvor.
A salt comprising: an anion of a KATP channel opener selected from the group consisting of Formula I to IV and a cation selected from the group consisting of a sodium cation, a potassium cation, choline, and hexamethyl hexamethylene diammonium, 
anion otvarača KATP kanala, kojeg se bira iz skupine koju čine Formula I do IV i kation, kojeg se bira iz skupine koju čine natrijev kation, kalijev kation, kolin i heksametil(heksametilen)diamonij, [image] gdje u Formuli I:
diazoxide, and a cation selected from the group consisting of choline and a potassium cation. 
diazoksid, i kation, kojeg se bira iz skupine koju čine kolin i kalijev kation.
The polymorph of a salt according to claim 2, wherein said cation is choline. 
Polimorf soli u skladu s patentnim zahtjevom 2, naznačen time što navedeni kation je kolin.
The polymorph of a salt according to claim 2, wherein said cation is potassium. 
Polimorf soli u skladu s patentnim zahtjevom 2, naznačen time što navedeni kation je kalij.
reacting one equivalent of a cation source selected from the group consisting of sodium hydroxide, potassium hydroxide, choline hydroxide, and hexamethyl hexamethylene diammonium dihydroxide with diazoxide, wherein said diazoxide is dissolved in a solvent selected from the group consisting of acetonitrile, methyl ethyl ketone (MEK), tetrahydrofurane (THF), and 2-methyltetrahydrofurane (2MeTHF), and removing the solvent. 
reakciji jednog ekvivalenta izvora kation, kojeg se bira iz skupine koju čine natrijev hidroksid, kalijev hidroksid, kolin-hidroksid, te heksametil(heksametilen)diamonijev dihidroksid s diazoksidom, gdje navedeni diazoksid se otopi u otapalu, kojeg se bira iz skupine koju čine acetonitril, metil-etil-keton (MEK), tetrahidrofuran (THF), te 2-metiltetrahidrofuran (2MeTHF), te se otapalo ukloni.
The formulation according to claim 8 that is suitable for oral administration. 
Formulacija u skladu s patentnim zahtjevom 8, naznačena time što je pogodna za oralnu primjenu.
maintaining weight loss in an obese, overweight, or obesity prone subject, comprising administering to said subject a therapeutically effective amount of said formulation; 
održavanje gubitka na težini kod pretilog, prekomjerno teškog ili subjekta sklonog pretilosti, što se sastoji u primjeni na navedenom subjektu terapijski djelotvorne količine navedene formulacije;
preventing the transition to diabetes of a prediabetic subject comprising administering to said subject a therapeutically effective amount of said formulation; 
sprječavanje prelaska u dijabetes predijabetičnog subjekta, što se sastoji u primjeni na navedenom subjektu terapijski djelotvorne količine navedene formulacije;
preventing or treating weight gain, dyslipidemia, diabetes or impaired glucose tolerance in a subject treated with an anti-psychotic drug, comprising administering to said subject a therapeutically effective amount of said formulation; 
sprječavanje ili liječenje dobivanja na težini, dislipidemije, dijabetesa ili smanjene tolerancije glukoza kod subjekta liječenog antipsihotikom, što se sastoji u primjeni na navedenom subjektu terapijski djelotvorne količine navedene formulacije;
treatment of a subject suffering from or at risk for Alzheimer's disease, comprising administering to said subject a therapeutically effective amount of said formulation; 
liječenje subjekta koji boluje od ili je u opasnosti da oboli od Alzheimerove bolesti, što se sastoji u primjeni na navedenom subjektu terapijski djelotvorne količine navedene formulacije;
treatment of a subject suffering from hypoglycemia, comprising administration to said subject a therapeutically effective amount of said formulation; or 
liječenje subjekta koji boluje od hipoglikemije, što se sastoji u primjeni na navedenom subjektu terapijski djelotvorne količine navedene formulacije; ili
The compound of Claim 1, where R1 is isobutyl, cyclopentyl, or thiophenyl. 
Spoj iz Patentnog zahtjeva 1, naznačen time, da je R1 izobutil, ciklopentil ili tiofenil.
reacting compound (3) with compound (6) to form compound (7): and 
reagiranje spoja (3) sa spojem (6) čime se dobiva spoj (7): [image] i
reacting compound (7) and compound (8) to provide a compound of formula I: 
reagiranje spoja (7) i spoja (8) čime se dobiva spoj formule I:
A compoud for use in therapy according to claim 21, for treating chronic obstructive pulmonary disease or asthma or for producing bronchodilation. 
Spoj koji se koristi u terapijske svrhe u skladu s patentnim zahtjevom 21, naznačen time, da se koristi za liječenje kronične opstruktivne plućne bolesti ili astme ili za bronhodilaciju.
A compound according to claim 10, or a pharmaceutically acceptable salt thereof, wherein R3 is methyl and the stereocentre produced has the (R)-configuration. 
Spoj u skladu s patentnim zahtjevom 10, ili njegova farmaceutski prihvatljiva sol, naznačen time, da R3 je metil, a dobiveni stereocentar ima (R)-konfiguraciju.
A compound according to any one of claims 1 to 26, or a pharmaceutically acceptable salt thereof, for use in the regulation of satiety or for use in the treatment of obesity or for use in the treatment of diabetes or for use in the treatment of metabolic syndrome (syndrome X), impaired glucose tolerance, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL levels or hypertension. 
Spoj u skladu s jednim od patentnih zahtjeva 1 do 26, ili njegova farmaceutski prihvatljiva sol, naznačen time, da se koristi za regulaciju sitosti, za liječenje pretilosti, za liječenje dijabetesa ili za liječenje metaboličkog sindroma (sindrom X), poremećene tolerancije na glukozu, hiperlipidemije, hipertrigliceridemije, hiperkolesterolemije, niskih razina HDL ili hipertenzije.
Method for producing a nicotine-containing product according to claim 1 or 2, characterized in that the solvent is selected from the group consisting of water, ethanol, methanol, 2-propanol, and mixtures thereof. 
Postupak proizvodnje proizvoda koji sadrži nikotin u skladu s patentnim zahtjevom 1 ili 2, naznačen time što se otapalo bira iz skupine koju čine voda, etanol, metanol, 2-propanol i njihove smjese.
Method for producing a nicotine-containing product according to claim 4, characterized in that the pharmaceutically acceptable substrate is a cation exchange resin selected from the group consisting of Amberlite® IR-20, Amberlite® IRP-69, Amberlite® IPR-64, Amberlite® IRP-58, Amberlite® IRC-50, and Amberlite® IRP-69. 
Postupak proizvodnje proizvoda koji sadrži nikotin u skladu s patentnim zahtjevom 4, naznačen time što je farmaceutski prihvatljiv supstrat kationsko-izmjenjivačka smola, koju se bira iz skupine koju čine Amberlite® IR-20, Amberlite® IRP-69, Amberlite® IPR-64, Amberlite® IRP-58, Amberlite® IRC-50, te Amberlite® IRP-69.